Phenotype and comparison groups
Define the most reliable functional phenotype and create comparison groups by response, model feature, dose or time.
R&D service
Mechanism & biomarker studies
Relate tissue, functional and molecular changes to the observed phenotype and identify response-associated biomarker candidates for further validation.
View imageMechanism and biomarkers across models
Connect tissue identity, molecular response and functional phenotype
HCC tissue–PDO histology and marker comparisons, kidney-injury qPCR and intestinal tight-junction imaging show how tissue, molecular and functional readouts can be combined around different mechanism questions.
Study focus
What this study can help you decide
- 01Which pathways change with the observed phenotype?
- 02Which biomarkers best distinguish response groups?
- 03Which results support the next study?
Study workflow
Connect reproducible phenotypes to mechanism and prioritize biomarker candidates
Compare baseline features, treatment response and mechanism readouts within the same model and batch context, then confirm key associations in additional samples, with orthogonal methods or repeat perturbation.
Mechanism-focused readout panel
Select histology, imaging, flow, qPCR, protein or secreted readouts around the candidate pathway so every readout serves the scientific question.
Data integration and biomarker candidates
Compare baseline features, treatment response and mechanism readouts within model and batch context to identify reproducible response-associated candidates.
Independent validation of candidate markers
Confirm key findings in additional samples, with orthogonal methods or repeat perturbation, then assess candidate-marker reproducibility and its relevance to mechanism or response groups.
Study images and readouts
From model characterization to study findings
Use tissue images, functional readouts and molecular assays to understand model identity, treatment response and differences across candidate strategies.
View imageH9-derived | cisplatin molecular response: RT-qPCR profiles KIM-1, H2AFX and inflammation/stress-related genes across cisplatin conditions, helping prioritize kidney-injury biomarkers and define follow-on dose, timing and confirmatory assays.
TRiCBIO H9-derived kidney organoid cisplatin studyView the kidney organoid injury study
View imageCytoskeleton and tight junctions: F-actin and ZO-1 immunofluorescence provides epithelial-structure and junction-status readouts.
TRiCBIO mouse intestinal organoid studyView the IBD model and barrier studyExpected study outputs
What you receive
Phenotype and molecular data
Functional, morphological, histological and molecular results from the agreed assays, with model and batch information.
Mechanistic insights & candidate markers
Integrate supporting findings, identify associations for follow-up testing and explain how candidate markers were selected.
Follow-up priorities and plan
Prioritized findings, orthogonal confirmation methods and additional sample requirements for the next study.
Relevant model systems
Recommended model systems
TRiCBIO studies in IBD barrier biology, kidney injury, tumor apoptosis and tumor immunity combine morphological, functional and molecular readouts. Candidate signals can then be advanced through additional samples, orthogonal methods and prespecified analyses to support mechanism and follow-on biomarker research.
PROJECT DISCUSSION
Connect phenotype and mechanism
Bring the observed phenotype, comparison groups, available data and mechanism hypothesis. Our scientists will connect molecular, functional and orthogonal assays around that question.